Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company’s first three microRNA-based tests, miRview™ squamous, miRview™ mets and miRview™ meso, are commercially available through its Philadelphia-based CLIA-certified lab. Rosetta Genomics is the 2008 winner of the Wall Street Journal’s Technology Innovation Awards in the medical/biotech category.

Technology

Rosetta Genomics is focused on developing microRNA-based diagnostic tests. microRNA’s unique qualities make them an ideal biomarker for a wide range of disease states and indications.

In order to unleash the power of microRNAs, Rosetta Genomics has developed a wide range of proprietary, highly sensitive technologies which enable it to identify, extract, and quantify microRNAs from body fluids and solid tumors.

Contact Details
Address: 10 Plaut St. Rehovot, Israel, 70760
Phone: +972 73 222 0700
Fax
Email: ron_ka@rosettagenomics    
Internet Site: www.rosettagenomics.com

Exhibition Representative
Name: Ron Kamienchick       
Mobile: +1 646 509 1893
E-mail: ron_ka@rosettagenomics.com 

Name: Ronen Tamir              
Mobile: +1 212 300 6712
E-mail: ronen_ta@rosettagenomics.com 

Category: Biotechnology